EUVIMEDEUVIMED entdecken
Crossref

High-dose-rate brachytherapy for airway malignancy a single institution experience

Zain Siddiqui, Conrad Falkson, Wilma Hopman, Aamer Mahmud

Brachytherapy · 2023

DOI: 10.1016/j.brachy.2023.04.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2023. Verfasst von Zain Siddiqui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Brachytherapy. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate clinical outcomes of endobronchial malignancy treated using high-dose-rate endobronchial brachytherapy (HDREB). METHODS AND MATERIALS: A retrospective chart review was conducted for all patients treated with HDREB for malignant airway disease between 2010 and 2019 at a single institution. Most patients had a prescription of 14 Gy in two fractions given a week apart. The Wilcoxon signed rank test and paired samples t test were used to compare changes in mMRC dyspnea scale prior to and after brachytherapy at first followup appointment. Toxicity data were collected for dyspnea, hemoptysis, dysphagia, and cough. RESULTS: A total of 58 patients were identified. Most (84.5%) had primary lung cancer with advanced cancers, stage III or IV (86%). Eight were treated while admitted in the ICU. Previous external beam radiotherapy (EBRT) was received by 52%. An improvement in dyspnea was seen in 72%, with an mMRC dyspnoea scale score improvement of 1.13 points (p < 0.001). Most (22, 88%) had an improvement in hemoptysis and 18 out of 37 (48.6%) had an improvement in cough. Grade four to five events occurred in 8 (13%) at the median time of 2.5 months from brachytherapy. Twenty-two patients (38%) had complete obstruction of the airway treated. Median progression free survival was 6.5 months and median survival was 10 months. CONCLUSIONS: We report a significant symptomatic benefit among patients receiving brachytherapy with endobronchial malignancy, with rates of treatment related toxicities similar to prior studies. Our study identified new subgroups of patients, ICU patients & those with complete obstruction, who benefited from HDREB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsBrachytherapyHumansHemoptysisCoughRetrospective StudiesTreatment OutcomeRadiotherapy DosageDyspnea

Stichwörter der Autor:innen

EBBEndobronchial brachytherapyHDRHDREBHigh-dose-rate endobronchial brachytherapyLung brachytherapy

Autor:innen und Institutionen

  • Department of Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
  • Depratment of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
  • Department of Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada. Electronic address: Aamer.Mahmud@kingstonhsc.ca.

Zitieren

APA

Siddiqui, Z., Falkson, C., Hopman, W., & Mahmud, A. (2023). High-dose-rate brachytherapy for airway malignancy a single institution experience. Brachytherapy. https://doi.org/10.1016/j.brachy.2023.04.001

Vancouver

Siddiqui Z, Falkson C, Hopman W, Mahmud A. High-dose-rate brachytherapy for airway malignancy a single institution experience. Brachytherapy. 2023. doi:10.1016/j.brachy.2023.04.001

BibTeX
@article{Siddiqui2023,
  author = {Siddiqui, Zain and Falkson, Conrad and Hopman, Wilma and Mahmud, Aamer},
  title = {High-dose-rate brachytherapy for airway malignancy a single institution experience},
  journal = {Brachytherapy},
  year = {2023},
  doi = {10.1016/j.brachy.2023.04.001}
}
Kostenlos starten →